Patents Assigned to The Research Foundation for Microbial Diseases
-
Patent number: 11633469Abstract: Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).Type: GrantFiled: July 11, 2017Date of Patent: April 25, 2023Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Takao Fujimoto, Junji Fujita
-
Patent number: 11186618Abstract: The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.Type: GrantFiled: September 21, 2017Date of Patent: November 30, 2021Assignee: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITYInventor: Yasuo Yoshioka
-
Publication number: 20210338798Abstract: Provided is a method of producing reassortant influenza virus containing an antigenic protein of the first influenza virus strain, the method including the following steps: 1) a step of irradiating the first influenza virus strain with ultraviolet light in such an irradiation dose that the first influenza virus strain has initial infection ability and loses or is reduced in virus growth potential; 2) a step of infecting a host with the first influenza virus strain and the second influenza virus strain; 3) a step of culturing the host infected with the first influenza virus strain and the second influenza virus strain, to obtain culture product; 4) a step of inactivating influenza virus strain having an antigenic protein of the second influenza virus strain in the culture product obtained in the step 3); and 5) a step of collecting reassortant influenza virus after the step 4).Type: ApplicationFiled: July 11, 2017Publication date: November 4, 2021Applicant: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Takao Fujimoto, Junji Fujita
-
Publication number: 20210261964Abstract: An object is to provide a technology that can stably exhibit the effects of A-type CpG oligodeoxynucleotides. The object can be achieved by a lipid particle comprising an A-type CpG oligodeoxynucleotide.Type: ApplicationFiled: July 18, 2019Publication date: August 26, 2021Applicants: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, OSAKA UNIVERSITY, TEIKYO UNIVERSITYInventors: Taiki AOSHI, Shohei KOYAMA, Ryo SUZUKI
-
Publication number: 20210062138Abstract: An object of the present invention is to provide a technique capable of further increasing the absolute detection value and/or the ratio of the detection value to a reference in a pneumococcal antibody sample evaluation test, or a technique capable of evaluating pneumococcal antibody samples against a wider variety of pneumococcal strains.Type: ApplicationFiled: January 17, 2019Publication date: March 4, 2021Applicant: THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITYInventors: Zhenyu PIAO, Yuka KOIZUMI, Hiroshi MIYATAKE
-
Publication number: 20180223326Abstract: The present invention relates to a measurement method for complement-dependent bactericidal activity against Streptococcus pneumoniae, and provides a measurement method capable of measuring complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype. Complement-dependent bactericidal activity against Streptococcus pneumoniae is measured using capsule-deficient Streptococcus pneumoniae, that is, non-encapsulated or substantially non-encapsulated, or transparent Streptococcus pneumoniae. The measurement of the complement-dependent bactericidal activity against Streptococcus pneumoniae of any capsular serotype is enabled.Type: ApplicationFiled: June 17, 2016Publication date: August 9, 2018Applicants: The Research Foundation For Microbial Diseases Of Osaka University, Osaka UniversityInventors: Yukihiro Akeda, Hiroshi Miyatake, Zhenyu Piao, Yuka Koizumi
-
Patent number: 9603919Abstract: The present invention provides a vaccine composition for transnasal mucous membrane administration, which contains an influenza virus antigen, polyriboinosinic polyribocytidylic acid (poly (I:C)) or a derivative thereof and a carboxyvinyl polymer. The present invention also provides a prophylactic method of influenza, including a step of administering the vaccine composition at least once to the nasal mucosa of a subject in need thereof.Type: GrantFiled: March 31, 2010Date of Patent: March 28, 2017Assignees: JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASES, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, TOKO YAKUHIN KOGYO KABUSHIKI KAISHAInventors: Hideki Hasegawa, Sadao Manabe, Takeshi Tanimoto, Takashi Miyazaki, Taizou Kamishita
-
Patent number: 9605053Abstract: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.Type: GrantFiled: February 5, 2016Date of Patent: March 28, 2017Assignees: Fujita Health University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Yoshikazu Kurosawa, Yoshitaka Iba, Nobuko Ohshima, Yoshinobu Okuno
-
Patent number: 9534042Abstract: Provided is an anti-influenza virus antibody that exhibits neutralizing activity beyond the barrier of the two groups of influenza viruses categorized according to the conservativeness of hemagglutinin amino acids, a method of producing the same, and a test method for determining whether the subject carries the neutralizing antibody.Type: GrantFiled: August 4, 2011Date of Patent: January 3, 2017Assignees: Fujita Health University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Yoshikazu Kurosawa, Yoshitaka Iba, Nobuko Ohshima, Yoshinobu Okuno
-
Patent number: 9493550Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: GrantFiled: October 3, 2014Date of Patent: November 15, 2016Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Publication number: 20160200799Abstract: It is an object of the present invention to provide a novel antibody having a high binding activity and a high neutralizing activity on influenza viruses. The present invention provides an antibody, which neutralizes H1 influenza virus and/or H5 influenza virus, wherein the antibody has a heavy chain variable region having CDRs consisting of a defined heavy chain first complementarity-determining region (VH CDR1), a defined heavy chain second complementarity-determining region (VH CDR2) and a defined heavy chain third complementarity-determining region (VH CDR3), and a light chain variable region having CDRs consisting of a defined light chain second complementarity-determining region (VL CDR2) and a defined light chain third complementarity-determining region (VL CDR3).Type: ApplicationFiled: August 20, 2014Publication date: July 14, 2016Applicants: FUJITA HEALTH UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, PERSEUS PROTEOMICS INC.Inventors: Yoshikazu KUROSAWA, Nobuko OSHIMA, Yoshinobu OKUNO, Katsuyuki MITOMO, Katsushi KOUDA
-
Patent number: 9181328Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.Type: GrantFiled: January 31, 2013Date of Patent: November 10, 2015Assignees: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCES MINISTRY OF PUBLIC HEALTHInventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
-
Patent number: 9045556Abstract: The present invention provides an adjuvant for cancer antigen peptide vaccines and virus antigen peptides, containing a pertussis vaccine as a primary ingredient. The present invention also provides a therapeutic agent for a cancer or viral infectious disease, and a prophylactic agent for metastasis or recurrence of cancer or onset of virus-induced tumor, containing a cancer antigen peptide or virus antigen peptide and a pertussis vaccine. A pertussis vaccine that can be suitably used is a whole cell body pertussis vaccine. The agents of the present invention can be safely administered in a plurality of doses.Type: GrantFiled: February 7, 2008Date of Patent: June 2, 2015Assignees: NEC Corporation, The Research Foundation for Microbial Disease of Osaka University, National University Corporation Kochi UniversityInventors: Keiko Udaka, Masahide Ishibashi
-
Patent number: 8975378Abstract: Provided is a human antibody having a neutralization activity against a human influenza virus. More specifically, provided is a human antibody which recognizes a highly conserved region in a human influenza A virus subtype H3N2 or a human influenza B virus and has a neutralization activity against the virus. The human antibody is a human anti-human influenza virus antibody, which has a neutralization activity against a human influenza A virus subtype H3N2 and binds to a hemagglutinin HA1 region of the human influenza A virus subtype H3N2, or which has a neutralization activity against a human influenza B virus, and includes, as a base sequence of a DNA encoding a variable region of the antibody, a sequence set forth in any one of SEQ ID NOS: 5 to 12.Type: GrantFiled: December 24, 2009Date of Patent: March 10, 2015Assignees: Osaka University, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Kazuyoshi Ikuta, Ritsuko Koketsu, Yoshinobu Okuno, Mikihiro Yunoki, Shoji Ideno, Masatoshi Oshita, Motoki Kuhara, Masatoshi Momota
-
Publication number: 20140377262Abstract: Materials and methods are provided for treating influenza B infections in humans. Anti-human influenza virus monoclonal antibodies and antigen-binding fragments thereof having a neutralization activity against a human influenza B virus are provided. Methods for producing anti-human influenza B virus monoclonal antibodies are also provided. The antibodies and antigen-binding fragments thereof can be effective against a wide range of influenza B viral strains. Methods of inhibiting or treating a human influenza B infection are provided. The anti-influenza B therapeutics can also be used to manufacture medicaments effective against influenza B infections, to detect human influenza B in a human subject, for use in pharmaceutical compositions, and for use in kits for at least one of the prevention, the treatment, and the detection of human influenza B in a human subject.Type: ApplicationFiled: January 31, 2013Publication date: December 25, 2014Applicants: OSAKA UNIVERSITY, THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, MEDICAL AND BIOLOGICAL LABORATORIES CO., LTD., DEPARTMENT OF MEDICAL SCIENCESInventors: Mayo Yasugi, Motoki Kuhara, Jotika Boon-Long, Kazuhito Fujiyama, Ritsuko Koketsu, Kazuyoshi Ikuta
-
Patent number: 8795687Abstract: The present invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.Type: GrantFiled: November 7, 2008Date of Patent: August 5, 2014Assignees: Japan as Represented by the Director-General of National Institute of Infections Diseases, The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Asato Kojima, Hidehiro Takahashi, Toyokazu Ishikawa
-
Publication number: 20140093526Abstract: The present invention addresses the problem of providing a vaccine which as yet has not been provided for the disease HHV-6B, which is the cause of exanthema subitum in infants, and the problem of providing an effective screening method for other therapeutic drugs. The above-mentioned problems are solved by providing an epitope specific to HHV-6B, of the amino acid sequence (QALCEGGHVFYNP) represented by positions 484 to 496 of SEQ ID NO: 2 or a modified sequence thereof, wherein the epitope either has a sequence comprising at least five consecutive amino acids including at least E, or a sequence that preserves the 487th C and 489th G when E is changed to Q.Type: ApplicationFiled: April 15, 2011Publication date: April 3, 2014Applicants: The Research Foundation for Microbial Diseases of Osaka University, National Institute of Biomedical InnovationInventors: Yasuko Mori, Koichi Yamanishi, Michiaki Takahashi
-
Publication number: 20140086927Abstract: Antibodies (Abs) play roles in protection against influenza. Neutralizing Abs either inhibit the binding of hemagglutinin (HA) to cellular receptors or prevent the conformational change of HA induced by low pH. The former Ab binds to the regions near the sialic acid-binding pocket on the globular head formed by HA1 and generally shows narrow strain specificity. The latter Ab binds to the stem region formed mainly by HA2 and shows broad strain specificity. We isolated a broadly neutralizing Ab against H3N2 viruses. X-ray analysis of the HA/Ab complex indicated that the Ab binds to the valley formed by two neighboring HA monomers at the side of the globular head. The Ab shows neutralizing activity by preventing the conformational change of HA induced at low pH.Type: ApplicationFiled: September 24, 2013Publication date: March 27, 2014Applicants: Fujita Health University, The Research Foundation for Microbial Diseases of Osaka University, Osaka UniversityInventors: Yoshikazu Kurosawa, Yoshitaka Iba, Nobuko Ohshima, Shigeyuki Yokoyama, Mikako Shirouzu, Yoshifumi Fujii, Tomomi Sumida, Kazuyoshi Ikuta, Shota Nakamura, Norihito Kawashita, Mitsuhiro Nishimura, Akifumi Yamashita, Yoshinobu Okuno, Ritsuko Kubota-Koketsu, Masahiro Okubo
-
Publication number: 20140065180Abstract: The invention provides virus-like particles (VLP) highly secreting or producing signal peptide obtained by altering a signal sequence derived from West Nile virus (WNV), the signal peptide, a WNV VLP secretion expression vector containing a nucleic acid encoding prM protein and E protein, a WNP VLP highly secreting or producing animal cell line harboring the vector, a WNV vaccine containing WNV VLP obtained by the cell line as an active ingredient, and a WNV DNA vaccine containing the VLP secretion expression vector as an active ingredient.Type: ApplicationFiled: November 4, 2013Publication date: March 6, 2014Applicants: The Research Foundation for Microbial Diseases of Osaka University, Japan as Represented by the Director-General of National Inst. of Infectious DiseasesInventors: Asato KOJIMA, Hidehiro TAKAHASHI, Toyokazu ISHIKAWA
-
Patent number: 8507443Abstract: The present invention is an antineoplastic agent characterized by including at least one of taxol and taxol derivatives and a protein which is a mutant of diphtheria toxin, having an activity to inhibit a binding between HB-EGF and EGFR and substantially not having a toxicity of diphtheria toxin as active ingredients.Type: GrantFiled: August 19, 2005Date of Patent: August 13, 2013Assignee: The Research Foundation for Microbial Diseases of Osaka UniversityInventors: Eisuke Mekada, Shingo Miyamoto